Elpen Pharmaceutical

What Elpen Pharmaceutical does

Elpen Pharmaceutical Co. Inc. (ΕΛΠΕΝ Α.Ε.) is a privately-held Greek pharmaceutical manufacturer founded in 1965 by Dimitrios Pentafragas, headquartered in Pikermi, Attica. The company manufactures and markets a portfolio of 30 pharmaceutical formulations across 13 therapeutic categories — including prescription drugs, over-the-counter (OTC) products, dietary supplements (the almora PLUS® line), herbal medicinal products (Canephron® Uno, Imupret®), and infant nutrition (Rontamil®) — serving an installed base of 10 million+ patients in Greece and 90+ international markets. Its core proprietary technology is Elpenhaler®, a dry powder inhaler (DPI) device for asthma and COPD treatment, patented in over 100 countries and authorized in 27 European countries, which constitutes the primary innovation asset and international expansion vehicle. The company also operates the Athens LifeTech Park (the first biotechnology park in Southeast Europe) and the largest private biomedical research laboratory in Greece, investing 15% of revenue in R&D annually.

The company earns revenue primarily through one-time sales of pharmaceutical products — both directly via subsidiaries (ELPEN Pharma GmbH in Germany since 2012; ELPEN Middle East Africa in Dubai since 2025) and through distribution partnerships across 90+ countries. A secondary revenue stream derives from licensing of the Elpenhaler® technology and contract manufacturing services to third parties. With 70% of total production exported and over 80% of profitability now generated from international operations (since 2025), Elpen is structurally an export-driven pharmaceutical manufacturer with 2026 projected exports exceeding €300 million. Customer segments include the Greek National Health System, German statutory insurance funds, retail pharmacies, healthcare professionals, and end patients. The company holds full EU GMP/GDP/GSP certifications, ISO 9001:2015, and GDPR compliance. The company employs 2,000+ people as of 2026 and remains family-controlled, with founder Dimitrios Pentafragas as Chairman and Theodore Tryfon as Vice President.

Name

Elpen Pharmaceutical

Legal name

ELPEN Pharmaceutical Co Inc.

Website

https://elpen.gr

Company type

Private

Founded year

1965

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Elpen Pharmaceutical is a family-owned Greek pharmaceutical manufacturer founded in 1965, producing 30 formulations across 13 therapeutic categories and exporting to 90+ countries. Its proprietary Elpenhaler® dry powder inhaler, patented globally, anchors its international expansion serving 10 million+ patients worldwide.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

Keywords

• Generic pharmaceuticals
• Drug delivery devices
• Respiratory therapeutics
• Dietary supplements
• Contract manufacturing

Headquarters

HQ city

Athens

HQ country

Greece

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Manufacturing and sale of branded and generic prescription pharmaceuticals, OTC products, and dietary supplements through pharmacies and healthcare institutions in domestic and international markets.
2. International Exports: Export of pharmaceutical products to 90+ countries through subsidiaries and distribution partners. Exports represent 70% of total production, with international sales exceeding domestic Greek market since 2025.
3. Licensing & Technology Transfer: Licensing of proprietary technology including Elpenhaler® device and manufacturing capabilities to international partners.
4. Contract Manufacturing Services: Services to third parties including manufacturing, licensing and distribution of generics, and co-promotion partnerships.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

Elpen Pharmaceutical (ELPEN A.E.) is a Greek pharmaceutical manufacturer that develops, produces and markets branded and generic prescription pharmaceuticals, OTC products, dietary supplements, herbal medicines and infant nutrition products, along with the proprietary Elpenhaler® dry powder inhaler device. The company operates two manufacturing facilities in Pikermi and Keratea (Attica, Greece), with a portfolio spanning 13 therapeutic categories and 30 formulations, serving healthcare institutions, pharmacies and consumers in 90+ countries.

Product overview

Elpen Pharmaceutical (ΕΛΠΕΝ Α.Ε.) is a Greek pharmaceutical company with over 60 years of experience manufacturing and exporting pharmaceutical products. The company operates a multi-product portfolio organized into three main categories: (1) Prescription Products covering 13 therapeutic areas with 30 branded and generic formulations including cardiovascular, respiratory, diabetes, and other treatments; (2) OTC/Consumer Health Products including the almora PLUS® line of dietary supplements (ZERO SUGAR, ENERGY, CEREBIOME®, REFLUX variants) as well as herbal medicinal products Canephron® Uno and Imupret®; and (3) the proprietary Elpenhaler® dry powder inhaler device for asthma and COPD treatment, which is patented in over 90 countries and authorized in 27 European countries. The company also offers infant nutrition products (Rontamil®) through its Rontis collaboration and third-party manufacturing services. Elpenhaler® serves as the company's flagship innovation driving international expansion, while the almora PLUS® line forms the core consumer health supplement brand.

Differentiator

Problem solved

Functional benefit

Brands

• Elpenhaler®: Proprietary dry powder inhaler device for treatment of asthma and COPD, patented in over 80-100 countries and approved in 27 European countries.
• almora PLUS®
• Canephron® Uno
• NeuroAge®
• Athens LifeTech Park
• Rolenium® Elpenhaler®
• Pulmelia® Elpenhaler®
• Imupret®
• Gopain®

Products and services

• Elpenhaler® Proprietary dry powder inhaler (DPI) device for the treatment of Asthma and Chronic Obstructive Pulmonary Disease (COPD). Features the fluticasone/salmeterol combination; first pharmaceutical company in the world to receive marketing authorization for this hybrid combination DPI. Patented in over 90 countries and authorized in 27 European countries. Sold under brand names Rolenium® Elpenhaler® and Pulmelia® Elpenhaler® in Germany.
• Prescription Pharmaceuticals (Συνταγογραφούμενα) Prescription-only branded and generic pharmaceutical products covering 13 therapeutic categories with 30 formulations, including treatments for cardiovascular, respiratory, diabetes, gastrointestinal, and other conditions. Sold to pharmacies, hospitals and healthcare institutions in Greece and 90+ international markets.
• OTC Pharmaceuticals (Μη συνταγογραφούμενα) Over-the-counter pharmaceutical products available without prescription for self-medication, sold through Greek and international pharmacy channels.
• almora PLUS® Dietary Supplements Line of branded dietary supplements including almora PLUS ZERO SUGAR, almora PLUS ENERGY, almora PLUS CEREBIOME®, almora PLUS REFLUX and related formulations addressing digestion, energy, hydration, psychological function and nutritional supplementation needs for consumers.
• Canephron® Uno Herbal medicinal product indicated for mild symptoms of urinary tract inflammation (cystitis), distributed in the Greek market under the partnership with Bionorica.
• Imupret® Herbal medicinal product for the relief of common cold symptoms including sore throat, difficulty swallowing, and cough due to cold.
• Rontamil® Infant Nutrition Infant nutrition product line including Rontamil AR for infant reflux (reductions) treatment, developed in collaboration with Rontis Corporation and exclusively distributed by ELPEN in Greece from December 2015.
• Gopain®

Quantifiable outcome

• 10 million+ patients served globally
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• WINMEDICAcoreStrategic or Co-development Partner · 1 January 2024Joint donation of vehicle and medical equipment for the 'OIKOTHEN' home healthcare program at Metaxa Hospital, supporting at-home patient treatments.
• BionoricacoreChannel Partner/ Reseller/ Distributor · 1 January 2022Partnership for exclusive distribution of herbal medicinal products (Herbal Medicinal Products) in the Greek market, bringing clinically documented botanical pharmaceuticals to Greek patients.
• Rontis CorporationcoreChannel Partner/ Reseller/ Distributor · 1 December 2015Exclusive promotion and distribution partnership for Rontamil infant nutrition products across Greece, expanding ELPEN's pediatric product portfolio.
• We4allminorOthersEnvironmental partnership supporting the 'Green Future' project with environmental education in schools and beach cleanup activities, involving employees in CSR initiatives.
• Hellenic Cancer SocietycoreStrategic or Co-development PartnerLong-standing partnership supporting the 'MAST Movement for Breast Cancer' campaign with mobile mammography unit sponsorship and free screening programs across Greece.
• Aegean TeamminorStrategic or Co-development Partner15+ year partnership providing medical equipment and supplies to rural clinics on remote Greek islands during the annual Aegean Sea Crossing.
• Takeda PharmaceuticalscoreChannel Partner/ Reseller/ DistributorDistribution partnership for alogliptin (DPP-4 inhibitor) for Type II Diabetes treatment, leveraging ELPEN's established trust with patients and medical community.
• Greek Universities and Medical InstitutionscoreStrategic or Co-development PartnerResearch and training collaborations including gastroenterology seminars, surgical training, and pharmaceutical education support at EKPA pharmacy school.
• Morphoses Technology CompanyminorOthersThird consecutive year partnership enhancing soft skills of employees' children through innovative programs.
• KEDE (Central Union of Hellenic Municipalities)minorStrategic or Co-development PartnerPartnership supporting municipal health initiatives and the 'MAST Movement for Breast Cancer' campaign under KEDE auspices.

Scale indicators13 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Stada Arzneimittel: German-based private (PE-owned) generics and specialty pharma company with broad European footprint and OTC presence. Closely comparable to ELPEN's mix of generics across multiple therapeutic areas plus consumer health brands, and shares the same European regulatory pricing environment.
• Krka: Slovenian generic and specialty pharma group with international expansion across CEE, Western Europe, and overseas markets. Similar profile to ELPEN: vertically integrated manufacturing, generics focus, export-driven growth, and strong regional brand.
• Almirall: Spanish specialty pharma with a strong dermatology and respiratory franchise including inhalation therapies. Comparable to ELPEN's Elpenhaler®-anchored respiratory specialty positioning within a broader European specialty pharma business.
• Chiesi Farmaceutici: Italian privately-held pharma with deep respiratory/inhalation expertise and global commercial reach. Highly comparable to ELPEN on inhalation drug-device combinations, European private-company governance, and global expansion model.
• Gedeon Richter: Hungarian pharma group with branded generics, specialty, and biotech operations across CEE and Western Europe. Similar in being a CEE-rooted, family-influenced pharma with strong export franchise and own-brand prescription portfolio.
• Dermapharm Holding: German specialty pharma with branded generics, OTC, and consumer health products. Comparable scale, business model, and European private/mid-cap positioning to ELPEN's specialty-plus-generics mix.
• Bionorica: German-based herbal/botanical pharma company that is also a distribution partner of ELPEN in Greece. Directly comparable in herbal medicinal product portfolio (Canephron®, Imupret®) and European regulatory positioning.

Broad incumbents

• Viatris: Global generics and specialty pharma major with extensive respiratory portfolio. Operates broadly in the same categories as ELPEN but at much greater scale and with a different capital structure.
• Teva Pharmaceutical Industries: World's largest generics company with significant respiratory franchise (including DPIs). A broad incumbent that competes with ELPEN across generic therapeutic categories and inhalation.
• Sandoz: Novartis's generics spinoff with global generic and biosimilar reach. Competes with ELPEN in generic prescription categories and represents the kind of large-scale competitor that compresses pricing in shared markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Elpen Pharmaceutical